Progressive osteoporosis during androgen deprivation therapy for prostate cancer

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 181-186

  Daniell, Harry W ^a   Dunn, Stephen R ^a   Ferguson, David W ^a   Lomas, Gregory ^a   Niazi, Ziad ^a   Stratte, P Tryg ^a  

^a NONE

Author keywords

Exercise therapy; Hypogonadism; Obesity; Osteoporosis; Prostate neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN;

AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE; FEMUR NECK; HUMAN; HYPOGONADISM; MALE; OBESITY; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; RISK FACTOR;

EID: 0033992101     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68000-7     Document Type: Article

References (30)

1. Jackson, J. A., Riggs, M. W. and Spiekerman, A. M.: Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci, 304: 4, 1992.
2. Seeman, E., Melton, L. J., III, O'Fallon, W. M. et al: Risk factors for spinal osteoporosis in men. Am J Med, 75: 977, 1983.
3. Kelepouris, N., Harper, K. D., Gannon, F. et al: Severe osteoporosis in men. Ann Intern Med, 123: 452, 1995.
4. Daniell, H. W.: Osteoporosis after orchiectomy for prostate cancer. J Urol, 157: 439, 1997.
5. Eriksson, S., Eriksson, A., Stege, R. et al: Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens. Calcif Tissue Int, 57: 97, 1995.
6. 6-GnRH). J Clin Endocrinol Metab, 76: 288, 1993.
7. Diamond, T., Campbell, J., Bryant, C. et al: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer, 83: 1561, 1998.
8. Deltombe, I., Prier, A. and Kaplan, G.: LHRH agonists and vertebral osteoporosis in men: two cases. Ann Med Interne (Paris), 146: 284, 1995.
9. Collinson, M. P., Tyrell, C. J. and Hutton, C.: Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int, 54: 327, 1994.
10. Horan, A. H.: Fractures ascribable to osteoporosis following LHRH antagonism for carcinoma of the prostate: a preliminary survey. J Bone Miner Res, 8: 763, 1993.
11. Maillefert, J. F., Sibilia, J., Kuntz, J. L. et al: Gonadotropin-releasing hormone agonists induce osteoporosis. Br J Rheumatol. 33: 1199, 1994.
12. Townsend, M. F., Sanders, W. H., Northway, R. O. et al: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer, 79: 545, 1997.
13. Anasti, J. N., Kalantaridou, S. N., Kimzey, L. M. et al: Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol, 91: 12, 1998.
14. Mazess, R. B., Barden, H. S., Drinka, P. J. et al: Influence of age and body weight on spine and femur bone mineral density in U.S. white men. J Bone Miner Res, 5: 645, 1990.
15. Luisetto, G., Bottega, F., Zangari, M. et al: Effects of three therapeutic regimens on post-menopausal bone loss in oophorectomized women. Curr Ther Res, 37: 839, 1996.
16. Genant, H. K., Cann, C. E., Ettinger, B. et al: Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med, 97: 699, 1982.
17. Stepan, J. J., Lachman, M., Zverina, J. et al: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab, 69: 523, 1989.
18. Maheux, R.: Treatment of fibroids with the combination of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. Adv Reprod Endocrinol, 4: 135, 1992.
19. Johansen, J. S., Riis, B. J., Hassager, C. et al: The effect of a gonadotropin-releasing hormone agonist analog (Nafarelin) on bone metabolism. J Clin Endocrinol Metab, 67: 701, 1988.
20. Scharla, S. H., Minne, H. W., Waibel-Treber, S. et al: Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1.25-dihydroxyvitamin D3. J Clin Endocrinol Metab, 70: 1055, 1990.
21. Matta, W. H., Shaw, R. W., Hesp, R. et al: Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J, 294: 1523, 1987.
22. Clarke, N. W., McClure, J. and George, N. J.: Preferential preservation of bone mineralisation by LHRH agonists in the treatment of metastatic prostate cancer. Eur Urol, 19: 114, 1991.
23. Goulding, A. and Gold, E.: Flutamide-mediated androgen blockade evokes osteopenia in the female rat. J Bone Miner Res, 8: 763, 1993.
24. Meyer, H. E., Tverdal, A. and Falch, J. A.: Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol, 137: 1203, 1993.
25. Daniell, H. W.: Osteoporosis of the slender smoker: vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch Intern Med, 136: 298, 1976.
26. Daniell, H. W.: A better prognosis for obese men with prostate cancer. J Urol, 155: 220, 1996.
27. Schneider, G., Kirschner, M. A., Berkowitz, R. et al: Increased estrogen production in obese men. J Clin Endocrinol Metab, 48: 633, 1979.
28. Need, A. G., Wishart, J. M., Scopacasa, F. et al: Effect of physical activity on femoral bone density in men. BMJ, 310: 1501, 1995.
29. Ryan, A.S., Treuth, M. S., Rubin, M. A. et al: Effects of strength training on bone mineral density: hormonal and bone turnover relationships. J Appl Physiol. 77: 1678, 1994.
30. Menkes, A., Mazel, S., Redmond, R. A. et al: Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men. J Appl Physiol, 74: 2478, 1993.